The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial
Open accessAbstract
Purpose: Decitabine, a DNA-targeted hypomethylating agent, is approved by the United States Food and Drug Administration for treatment of patients with myelodysplastic syndromes (MDS) on a schedule of 15 mg/m 2 administered via intravenous (IV) infusion every 8 hours for 3 days. This study assessed the efficacy and safety of an alternative dosing regimen administered on an outpatient basis in academic and community-based practices. Patients and Methods: Patients were treated with decitabine 20 mg/m 2 by IV infusion daily for 5 consecutive days every 4 weeks. Eligible patients were ≥ 18 years of age and had MDS (de novo or secondary) of any French-American-British (FAB) subtype and an International Prognostic Scoring System (IPSS) score ≥ 0.5. The primary end point was the overall response rate (ORR) by International Working Group (IWG 2006) criteria; secondary end points included cytogenetic responses, hematologic improvement (HI), response duration, survival, and safety. Results: Ninety-nine patients were enrolled; the ORR was 32% (17 complete responses [CR] plus 15 marrow CRs [mCRs]), and the overall improvement rate was 51%, which included 18% HI. Similar response rates were observed in all FAB subtypes and IPSS risk categories. Among patients who improved, 82% demonstrated responses by the end of cycle 2. Among 33 patients assessable for a cytogenetic response, 17 (52%) experienced cytogenetic CR (n = 11) or partial response (n = 6). Conclusion: Decitabine given on a 5-day schedule provided meaningful clinical benefit for patients with MDS, with more than half demonstrating improvement. This suggests that decitabine can be administered in an outpatient setting with comparable efficacy and safety to the United States Food and Drug Administration–approved inpatient regimen.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cellular differentiation, cytidine analogs and DNA methylation
Jones, P. A., & Taylor, S. M. (1980) · Cell · doi:10.1016/0092-8674(80)90237-8 · Cited by 1,831 · cited 1×
“Although the precise mechanism of the clinical efficacy of decitabine is uncertain, two mechanisms of action have been proposed: direct cytotoxicity and hypomethylation, which may induce cell differentiation, reduce proliferation, and increase apoptosis.(4,5) Two phase II clinical trials(6) of decitabine in patientswi…”
BackgroundCheson, B. D. (2006) · Blood · doi:10.1182/blood-2005-10-4149 · Cited by 1,580
Kantarjian, H., Issa, J. J., Rosenfeld, C. S., Bennett, J. M., Albitar, M., DiPersio, J., Klimek, V., Slack, J., de Castro, C., Ravandi, F., et al. (2006) · Cancer · doi:10.1002/cncr.21792 · Cited by 1,530
Self-citationKantarjian, H., Oki, Y., Garcia-Manero, G., Huang, X., O'Brien, S., Cortes, J., Faderl, S., Bueso-Ramos, C., Ravandi, F., Estrov, Z., et al. (2007) · Blood · doi:10.1182/blood-2006-05-021162 · Cited by 685
Self-citationCheson, B. D., Bennett, J. M., Kantarjian, H. M., Pinto, A., Schiffer, C. A., Nimer, S. D., Löwenberg, B., Beran, M., de Witte, T. M., Stone, R. M., et al. (2000) · PubMed · Cited by 666
Self-citationChanges in DNA Methylation in Neoplasia: Pathophysiology and Therapeutic Implications
Santini, V., Kantarjian, H. M., & Issa, J.-P. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-7-200104030-00011 · Cited by 414
Self-citationGreenberg, P. L., Attar, E., Bennett, J. M., Bloomfield, C. D., De Castro, C. M., Deeg, H. J., Foran, J. M., Gaensler, K., Garcia-Manero, G., Gore, S. D., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0005 · Cited by 290
Self-citationBow, E. J., Laverdière, M., Lussier, N., Rotstein, C., Cheang, M. S., & Ioannou, S. (2002) · Cancer · doi:10.1002/cncr.10610 · Cited by 258
DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias.
Leone, G. G. M., Teofili, L., Voso, M. T., & Lübbert, M. (2002) · PubMed · Cited by 200
Pinto, A., & Zagonel, V. (1993) · PubMed · Cited by 133
Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML)
Wijermans, P., Rüter, B. H., Baer, M. R., Slack, J. L., Saba, H. I., & Lübbert, M. (2007) · Leukemia Research · doi:10.1016/j.leukres.2007.08.004 · Cited by 129
Self-citationActivity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia
Aribi, A. M., Borthakur, G. M., Ravandi, F., Shan, J., Davisson, J., Cortes, J. E., & Kantarjian, H. M. (2007) · Cancer · doi:10.1002/cncr.22457 · Cited by 128
Self-citationKantarjian, H. M., O'Brien, S. M., Shan, J., Aribi, A. M., Garcia‐Manero, G., Jabbour, E. J., Ravandi, F., Cortes, J. E., Davisson, J., & Issa, J. J. (2006) · Cancer · doi:10.1002/cncr.22376 · Cited by 115
Self-citationWijermans, P., Lübbert, M., Verhoef, G. E. G., Klimek, V. M., & Bosly, A. (2005) · Annals of Hematology · doi:10.1007/s00277-005-0012-1 · Cited by 104
Superiority of prolonged low‐dose azanucleoside administration?
Rüter, B. H., Wijermans, P., & Lübbert, M. (2006) · Cancer · doi:10.1002/cncr.21796 · Cited by 63
Cited by
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients
Bejar, R., Lord, A., Stevenson, K., Bar-Natan, M., Pérez-Ladaga, A., Zaneveld, J., Wang, H., Caughey, B., Stojanov, P., Getz, G., et al. (2014) · Blood · doi:10.1182/blood-2014-06-582809 · Cited by 562
Self-citationLübbert, M., Suciu, S., Baila, L., Rüter, B. H., Platzbecker, U., Giagounidis, A., Selleslag, D., Labar, B., Germing, U., Salih, H. R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.9245 · Cited by 552
Cashen, A. F., Schiller, G. J., O'Donnell, M. R., & DiPersio, J. F. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.9178 · Cited by 464
Blum, W., Garzon, R., Klisovic, R. B., Schwind, S., Walker, A., Geyer, S., Liu, S., Havelange, V., Becker, H., Schaaf, L., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002650107 · Cited by 450
Adès, L., Itzykson, R., & Fenaux, P. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61901-7 · Cited by 393
Metadata
- Authors
- Steensma, D. P., Baer, M. R., Slack, J. L., Buckstein, R., Godley, L. A., Garcia-Manero, G., Albitar, M., Larsen, J. S., Arora, S., Cullen, M. T., & Kantarjian, H.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-08-10
- Volume
- 27
- Issue
- 23
- Pages
- 3842-3848
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2169007954
- Cited by
- 319
- References
- 15
- FWCI
- 18.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.